The emerging role of interleukin-1β in autoinflammatory diseases

Resistant Behçet Disease Responsive to Anakinra

(2013) Costantino Botsios et al.   ANNALS OF INTERNAL MEDICINE

REMISSION OF SCHNITZLER SYNDROME AFTER TREATMENT WITH ANAKINRA

(2010) Pamela A. Frischmeyer-Guerrerio et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Interleukin-1 antagonism in acute gout: Is targeting a single cytokine the answer?

(2010) Tuhina Neogi   ARTHRITIS AND RHEUMATISM

The Inflammasomes: Guardians of the Body

(2009) Fabio Martinon et al.   Annual Review of Immunology

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

(2009) Bénédicte Neven et al.   ARTHRITIS AND RHEUMATISM

Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease

(2009) Yelda Bilginer et al.   CLINICAL RHEUMATOLOGY

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

(2009) C. M. Larsen et al.   DIABETES CARE

Anakinra for Systemic Juvenile Arthritis

(2009) Andrew Zeft et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

(2009) John A. Lust et al.   MAYO CLINIC PROCEEDINGS

An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist

(2009) Ivona Aksentijevich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Autoinflammatory Disease Due to Homozygous Deletion of theIL1RNLocus

(2009) Sreelatha Reddy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome

(2008) A Delluc et al.   ANNALS OF THE RHEUMATIC DISEASES

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome

(2008) Raphaela Goldbach-Mansky et al.   ARTHRITIS AND RHEUMATISM

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome

(2008) M. Gattorno et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM

The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF- B through its N-terminal fragment

(2008) J. J. Chae et al.   BLOOD

The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies

(2008) Rachel L. Glaser et al.   CURRENT ALLERGY AND ASTHMA REPORTS

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

(2008) George D Kalliolias et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy of anakinra in a patient with refractory relapsing polychondritis

(2008) Daniel Wendling et al.   JOINT BONE SPINE

Schnitzler syndrome: a dramatic improvement with anakinra

(2008) H Wastiaux et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome

(2008) Jeroen C. H. van der Hilst et al.   MEDICINE

The Nalp3 inflammasome is essential for the development of silicosis

(2008) Suzanne L. Cassel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

(2008) Rieke Alten et al.   ARTHRITIS RESEARCH & THERAPY